---
schema_version: "secwatch.filing_event.v1"
accession: "0001380106-26-000067"
form_type: "8-K"
ticker: "RPID"
cik: "0001380106"
company_name: "RAPID MICRO BIOSYSTEMS, INC."
filed_at: "2026-05-13T20:33:24+00:00"
generated_at: "2026-05-13T20:34:52.340749+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rapid Micro Biosystems Q1 revenue up 11% to $8.0M; net loss widens to $14.3M

## Summary
- Total revenue $8.0M (+11% YoY); product revenue $5.6M (+36%).
- Net loss $14.3M ($0.31/sh) vs $11.3M ($0.26/sh) in Q1 2025.
- Recurring revenue $5.1M (+28%), 63% of total; placed 6 Growth Direct systems (3 in Q1 2025).
- Gross margin 4.6% vs 5.6% last year; cash and equivalents $23M.
- Reaffirms FY2026 guidance: revenue $37-41M, 30-38 system placements, ~20% gross margin.

## SEC filing metadata
- accession: 0001380106-26-000067
- form_type: 8-K
- ticker: RPID
- cik: 0001380106
- company_name: RAPID MICRO BIOSYSTEMS, INC.
- filed_at: 2026-05-13T20:33:24+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1380106/000138010626000067/0001380106-26-000067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1380106/000138010626000067/rpid-20260513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001380106-26-000067
- JSON: https://secwatch.observer/filing/0001380106-26-000067.json
- Plain text: https://secwatch.observer/filing/0001380106-26-000067.txt

## Key facts
- Earnings Releases
  RAPID MICRO BIOSYSTEMS, INC. reported full year 2026 results: revenue full year 2026 total revenue guidance range of $37.0 million to $41.0 million. Guidance reaffirmed.
  - Period: full year 2026
  - Revenue: full year 2026 total revenue guidance range of $37.0 million to $41.0 million
  - Guidance: reaffirmed
  - Result: guidance update
  source text: Reaffirms full year 2026 total revenue guidance range of $37.0 million to $41.0 million including a range of 30 to 38 Growth Direct system placements
  evidence_url: https://www.sec.gov/Archives/edgar/data/1380106/000138010626000067/0001380106-26-000067-index.htm
- Earnings Releases
  RAPID MICRO BIOSYSTEMS, INC. reported first quarter ended March 31, 2026 results: revenue Total revenue for the first quarter of 2026 increased 11.1% to $8.0 million compared to $7.2 million in the first quarte, net income Net loss for the first quarter of 2026 was $14.3 million, EPS net loss per share was $0.31.
  - Period: first quarter ended March 31, 2026
  - Revenue: Total revenue for the first quarter of 2026 increased 11.1% to $8.0 million compared to $7.2 million in the first quarte
  - Net income: Net loss for the first quarter of 2026 was $14.3 million
  - EPS: net loss per share was $0.31
  - Result: reported results
  source text: Total revenue for the first quarter of 2026 increased 11.1% to $8.0 million compared to $7.2 million in the first quarter of 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1380106/000138010626000067/0001380106-26-000067-index.htm
- Earnings Releases
  RAPID MICRO BIOSYSTEMS, INC. reported first quarter ended March 31, 2026 results: revenue Total revenue for the first quarter of 2026 increased 11.1% to $8.0 million compared to $7.2 million in the first quarte, net income Net loss for the first quarter of 2026 was $14.3 million, EPS net loss per share was $0.31.
  - Period: first quarter ended March 31, 2026
  - Revenue: Total revenue for the first quarter of 2026 increased 11.1% to $8.0 million compared to $7.2 million in the first quarte
  - Net income: Net loss for the first quarter of 2026 was $14.3 million
  - EPS: net loss per share was $0.31
  - Result: reported results
  source text: Net loss for the first quarter of 2026 was $14.3 million and net loss per share was $0.31, compared to a net loss of $11.3 million and net loss per share of $0.26 in the first quarter of 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1380106/000138010626000067/0001380106-26-000067-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.